Prabakaran Ponraj

Dr. Prabakaran Ponraj


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2016 in Antibodies
Verified
Journal Article
Open access
PDF file
WLWei Li
Wei Li
PPPrabakaran Ponraj
Prabakaran Ponraj
WCWeizao Chen
Weizao Chen
ZZZhongyu Zhu
Zhongyu Zhu
YFYang Feng
Yang Feng
DDDimiter S. Dimitrov
Dimiter S. Dimitrov
Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to emerging infectious diseases. Aggregation of mAbs continues to be a major problem in their developability. Antibody aggregation could be triggered by partial unfolding of its domains, leading to monomer-monomer association followed by nucleation and growth. Although the aggregation propensities of antibodies and antibody-based proteins can be affected by the external experimental conditions, they are strongly dependent on the intrinsic antibody properties as determined by their sequences and structures. In this review, we describe how the unfolding and aggregation susceptibilities of IgG could be related to their cognate sequences and structures. The impact of antibody domain structures on thermostability and aggregation propensities, and effective strategies to reduce aggregation are discussed. Finally, the aggregation of antibody-drug conjugates (ADCs) as related to their sequence/structure, linker payload, conjugation chemistry and drug-antibody ratio (DAR) is reviewed.

2 April 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Tianlei YingTianlei Ying
Tianlei Ying
TJTina W. Ju
Tina W. Ju
YWYanping Wang
Yanping Wang
PPPrabakaran Ponraj
Prabakaran Ponraj
DDDimiter S. Dimitrov
Dimiter S. Dimitrov
Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome this problem is through the development of novel antibody fragments based on IgG Fc region, which contributes to the long half-life of IgG through its unique pH-dependent association with the neonatal Fc receptor (FcRn). The IgG Fc region comprises two CH2 and two CH3 domains. In this report, we present a comparative study of the FcRn binding capability of the CH2 and CH3 domains. The stability and aggregation resistance of these domains were also investigated and compared. We found that monomeric CH2 and CH3 domains exhibited the pH-dependent FcRn binding while the dimeric forms of CH2 and CH3 domains did not. Although all of these domains had high serum stability, they had aggregation tendencies as measured by dynamic light scattering. By providing a better understanding of the structure-activity relationship of the Fc fragment, these results guide further approaches to generate novel Fc-based small-size antibody fragments that possess pH-dependent FcRn binding capability, desired in vivo half-lives and other favorable biophysical properties for their drugability.

24 January 2014 in Biomedicines
Verified
Journal Article
Open access
PDF file
YFYang Feng
Yang Feng
ZZZhongyu Zhu
Zhongyu Zhu
WCWeizao Chen
Weizao Chen
PPPrabakaran Ponraj
Prabakaran Ponraj
KLKedan Lin
Kedan Lin
DDDimiter S. Dimitrov
Dimiter S. Dimitrov
Conjugates of small molecule drugs with antibodies (ADCs) and with other proteins (protein-drug conjugates, PDC) are used as a new class of targeted therapeutics combining the specificity of monoclonal antibodies (mAbs) and other proteins with potent cytotoxic activity of small molecule drugs for the treatment of cancer and other diseases. A(P)DCs have three major components, antibody (targeting protein), linker and payload, the cytotoxic drug. Recently, advances in identifying targets, selecting highly specific mAbs of preferred isotypes, optimizing linker technology and improving chemical methods for conjugation have led to the approval of two ADCs by Food and Drug Administration (FDA) and more than 30 ADCs in advanced clinical development. However, the complex and heterogeneous nature of A(P)DCs often cause poor solubility, instability, aggregation and eventually unwanted toxicity. This article reviews the main components of A(P)DCs, and discusses the choices for drugs, linkers and conjugation methods currently used. Future work will need to focus on developments and strategies for overcoming such major problems associated with the A(P)DCs.

1 June 2020 in Cell Reports
Verified
Journal Article
Open access
PPPrabakaran Ponraj
Prabakaran Ponraj
Partha ChowdhuryPartha Chowdhury
Partha Chowdhury
Human antibody repertoire data captured through next-generation sequencing (NGS) has enabled deeper insights into B cell immunogenetics and paratope diversity. By analyzing large public NGS datasets, we map the landscape of non-canonical cysteines in human variable heavy-chain domains (VHs) at the repertoire level. We identify remarkable usage of non-canonical cysteines within the heavy-chain complementarity-determining region 3 (CDR-H3) and other CDRs and framework regions. Furthermore, our study reveals the diversity and location of non-canonical cysteines and their associated motifs in human VHs, which are reminiscent of and more complex than those found in other non-human species such as chicken, camel, llama, shark, and cow. These results explain how non-canonical cysteines strategically occur in the human antibodyome to expand its paratope space. This study will guide the design of human antibodies harboring disulfide-stabilized long CDR-H3s to access difficult-to-target epitopes and influence a paradigm shift in developability involving non-canonical cysteines.

1 January 2012 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
PPPrabakaran Ponraj
Prabakaran Ponraj
ZZZhongyu Zhu
Zhongyu Zhu
WCWeizao Chen
Weizao Chen
RGRui Gong
Rui Gong
YFYang Feng
Yang Feng
DDDimiter S. Dimitrov
Dimiter S. Dimitrov
Our understanding of how antibodies are generated and function could help develop effective vaccines and antibody-based therapeutics against viruses such as HIV-1, SARS coronavirus (SARS CoV), and Hendra and Nipah viruses (henipaviruses). Although broadly neutralizing antibodies (bnAbs) against the HIV-1 were observed in patients, elicitation of such bnAbs remains a major challenge when compared to other viral targets. We previously hypothesized that HIV-1 could have evolved a strategy to evade the immune system due to absent or very weak binding of germline antibodies to the conserved epitopes that may not be sufficient to initiate and/or maintain an effective immune response. To further explore our hypothesis, we used the 454 sequence analysis of a large naïve library of human IgM antibodies which had been used for selecting antibodies against SARS CoV receptor-binding domain (RBD), and soluble G proteins (sG) of henipaviruses. We found that the human IgM repertoires from the 454 sequencing have diverse germline usages, recombination patterns, junction diversity, and a lower extent of somatic mutation. In this study, we identified antibody maturation intermediates that are related to bnAbs against the HIV-1 and other viruses as observed in normal individuals, and compared their genetic diversity and somatic mutation level along with available structural and functional data. Further computational analysis will provide framework for understanding the underlying genetic and molecular determinants related to maturation pathways of antiviral bnAbs that could be useful for applying novel approaches to the design of effective vaccine immunogens and antibody-based therapeutics.

26 July 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
PDPawel Dudzic
Pawel Dudzic
DCDawid Chomicz
Dawid Chomicz
WBWeronika Bielska
Weronika Bielska
IJIgor Jaszczyszyn
Igor Jaszczyszyn
MZMichał Zieliński
Michał Zieliński
KKKonrad Krawczyk
Konrad Krawczyk
Understanding the pairing preferences and structural interactions between antibody heavy and light chains can enhance our ability to design more effective and specific therapeutic antibodies. Insights from natural antibody repertoires and conserved contact sites help reduce autoreactivity and improve drug safety and efficacy. Current databases represent only a limited portion of the estimated diversity of unique paired antibody molecules. To address this, we introduce PairedAbNGS, a novel database with paired heavy/light antibody chains. To our knowledge, this is the largest resource for paired natural antibody sequences with 58 bioprojects and over 14 million assembled productive sequences. Using this dataset, we investigated heavy and light chain variable (V) gene pairing preferences and found significant biases beyond gene usage frequencies, possibly due to receptor editing favoring less autoreactive combinations. Analyzing the available antibody structures from the Protein Data Bank, we studied conserved contact residues between heavy and light chains, particularly interactions between the CDR3 region of one chain and the FWR2 region of the opposite chain. Examination of amino acid pairs at key contact sites revealed significant deviations of amino acids distributions compared to random pairings, in the heavy chain’s CDR3 region contacting the opposite chain, indicating specific interactions might be crucial for proper chain pairing. This observation is further reinforced by preferential IGHV-IGLJ and IGLV-IGHJ pairing preferences. We hope that both our resources and the findings would contribute to improving the engineering of biological drugs. We make the database accessible at https://naturalantibody.com/paired-ab-ngs as a valuable tool for biological and machine-learning applications.